Annual Production for 2025 of 50,238 Gold Equivalent Ounces (“GEO”); and AISC of US$1,746 per ounce, in line with guidance 2026 Production guidance of 50,000 to 60,000 GEO weighted to H2/26 Adjusted EBITDA of $22.3 million for Q4, and $46.1 million for the full year Completed hedging program provides full future leverage to high gold prices Exited the year with a strong cash position of over $22 million Management to host Conference Call to discuss the financial and operational results on [April 2nd, 2025, at 11:00 AM EDT]TORONTO, April 02, 2026 (GLOBE NEWSWIRE) — Cerrado Gold Inc. [TSX.V:CERT][OTCQX:CRDOF; FRA:BAI0] (“Cerrado” or the “Company”) announces its operational and financial results for the fourth quarter (“Q4/25”), including its Minera Don Nicolas (“MDN”) gold project in Santa Cruz Province, Argentina, the highly...

EAGAN, Minn., April 01, 2026 (GLOBE NEWSWIRE) — Today the Blue Cross and Blue Shield of Minnesota family of companies (Blue Cross) reported a combined $353 million in operating losses on $10.4 billion in fully insured premium revenue for 2025. This represents an operating margin loss of approximately 3 percent. The reported operating loss includes a premium deficiency reserve of $150 million to cover continued claims expenses that exceed forecasted premium revenue. Strong investment portfolio performance resulted in Blue Cross closing out the year with a positive net income of $83 million. Overall, Blue Cross paid $9.8 billion for members’ medical and pharmacy services in 2025, or nearly $27 million in claims on a daily basis. This represents an increase of $1.7 billion in claims spending over the year prior. Unfavorable performance...

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), a leading provider of wellness solutions for people on the go, today announced financial results for the year ended December 31, 2025. Recent Operating HighlightsXWELL delivered 2025 revenue of approximately $29.2 million. Total operating expenses decreased by approximately 10% versus the comparable prior year period. Cost of sales decreased approximately 13% versus 2024.   General and administrative expenses decreased approximately 20% year-over-year. In December 2025, the Company opened a new wellness retail location in New York City’s Pennsylvania Station. In February 2026, XWELL entered into a strategic partnership with PieQ, an AI and predictive intelligence company, to develop a novel U.S. biosecurity...

TULSA, Okla., April 01, 2026 (GLOBE NEWSWIRE) — ONEOK, Inc. (NYSE: OKE) will release first-quarter 2026 earnings after the market closes on April 28, 2026. Members of ONEOK’s management team will participate in a conference call the following day. What:               ONEOK first-quarter 2026 earnings conference call and webcast When:              April 29, 2026, at 11 a.m. Eastern (10 a.m. Central) Where:            1) Conference call: Dial 800-343-5172 and use conference ID: OKE1Q26                         2) Webcast: Join at www.oneok.com If you are unable to participate in the conference call or the webcast, a recording will be available at www.oneok.com for one year. ——————————————————————————————————————————————————————————————– At...

ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) — Great Estate Blockchain, Inc. (OTC: VAYK), formerly known as Vaycaychella, Inc., reported over $2.0 million in revenue with close to $500,000 in operating profit for the fiscal year of 2025. This represents approximately 300% revenue growth over the same period last year. Meanwhile, the Board of Directors of the company issued the following statement with respect to potential business events of significance. STATEMENT OF BOARD OF DIRECTORS “Later last year, our Company (Great Estate Blockchain Inc. formerly known as Vaycaychella, Inc) announced, via a series of news releases, that we were pursuing a cryptocurrency and blockchain strategy to supplement our existing business. At the time the initiative was launched, this blockchain strategy appeared to have meaningful potential to contribute...

Press Release | April 1st, 2026, 5:45 pm IN A CHALLENGING ENVIRONMENT, SYNERGIE MAINTAINS ITS GROWTH TRAJECTORY AND OPERATIONAL PROFITABILITY Revenue: €3,241 million EBITDA: €134.4 million Net profit: €54.2 million On April 1st, 2026, the Synergie Board of Directors, chaired by Mr. Victorien Vaney, approved the consolidated full year financial statements for the period ended December 31st, 2025. The auditing procedures for these financial statements are complete, and the corresponding reports are being issued.Consolidated – in € million 2025 2024 Variation %Revenue 3,241.2 3 184.9 +1.8%EBITDA (1) 134.4 130.6 +2.9%EBITA (2) 102.6 103.7 -1.1%Operating profit 89.3 95.6 -6.6%Net profit 54.2 67.1 -19.2%Net profit group share 54.2 63.1 -14.1%(1)Current operating profit before depreciation of operating fixed assets and...

TERRITORIES OF MUSQUEAM, SQUAMISH AND TSLEIL-WAUTUTH NATIONS and VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) — Vancity has released its 2025 financial results, demonstrating strong profitability and a record $41 billion in assets plus assets under administration. Canada’s largest B.C.-based financial institution is entering 2026 with momentum and a focus on continued impact, growth and member experience. Amid a shifting economic environment, Vancity posted $69.9 million in net income in 2025, a dramatic improvement in performance from 2024’s modest profit of $5.8 million. In 2025, core revenue was $675.4 million — up more than 30% from 2024 — reflecting strong demand for Vancity’s values-based products and services across its consumer, wealth and business banking portfolios. Net lending growth of almost $1 billion...

LONDON, April 1, 2026 – Stolt-Nielsen Limited (Oslo Børs: SNI) will host a virtual presentation to discuss the Company’s unaudited results for the first quarter of 2026 on Thursday, April 9, 2026 at 15:00 CEST (09:00 EDT, 14:00 BST). The virtual presentation will be hosted by: –           Udo Lange – Chief Executive Officer, Stolt-Nielsen Limited –           Jens F. Grüner-Hegge – Chief Financial Officer, Stolt-Nielsen Limited–           Alex Ng – Vice President Strategy & Business Development, Stolt-Nielsen Limited To join the event online, please click here. The link will also be available on our website. It may be necessary to download the Teams app to join by mobile phone, although attendees should not need to log in or create an account. The presentation slides will be published on the Investor...

Accelerating Enterprise Adoption of Cloud-Based AI Video Surveillance Platform Drives 304% Increase in Gross Profit  Conference Call to Be Held Today at 12:00 pm ET. PALO ALTO, Calif., April 01, 2026 (GLOBE NEWSWIRE) — Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”), a leader in AI-powered video surveillance and remote monitoring, today reported financial results for the year ended December 31, 2025 and provided an update on the Company’s progress following its Nasdaq debut in January 2025. Adoption of the Company’s cloud-based AI video surveillance platform accelerated across multiple industries, driving strong financial and operational momentum. Revenue for the year totaled $5.1 million, compared to $1.4 million in 2024, representing approximately 271% year-over-year growth. “2025 marked...

CALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced financial results for the quarter and year ended December 31, 2025, and provided an update on recent operational achievements and upcoming milestones. Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented: “Q4 2025 and early 2026 marked important inflection points for NeOnc. We completed NEO212’s Phase 1 dose escalation and established a recommended Phase 2 dose of 610 mg, with early signs of possible anti-tumor activity in heavily pretreated patients. In parallel, the NEO100 Phase 2a study in recurrent IDH1-mutant high-grade glioma...